Monday, December 4, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
-
Disclosures for additional planners can be found here.
Professor
University of Milan
Director of the Division of Early Drug Development
European Institute of Oncology
Milan, Italy
Nurse Practitioner
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Los Angeles, California, United States
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, California, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity is intended for hematology/oncology specialists, surgeons, and obstetricians/gynecologists.
The goal of this activity is for learners to better communicate with patients who have hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) when discussing adjuvant therapy, with the aim of improving patient adherence to and persistence of therapy.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
-
Disclosures for additional planners can be found here.
Professor
University of Milan
Director of the Division of Early Drug Development
European Institute of Oncology
Milan, Italy
Nurse Practitioner
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Los Angeles, California, United States
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, California, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / CE Released: 11/28/2022
Valid for credit through: 11/28/2023, 11:59 PM EST
processing....
Download the pdf.
| « Return to: The Patient Journey in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Best Practices for Communication and Shared Decision-making |
